000 04394nam a22005897a 4500
001 sulb-eb0025160
003 BD-SySUS
005 20160413122513.0
007 cr nn 008mamaa
008 131004s2013 gw | s |||| 0|eng d
020 _a9783642386640
_9978-3-642-38664-0
024 7 _a10.1007/978-3-642-38664-0
_2doi
050 4 _aRM1-950
072 7 _aMMG
_2bicssc
072 7 _aMED071000
_2bisacsh
082 0 4 _a615
_223
245 1 0 _aPharmacotherapy of Pulmonary Hypertension
_h[electronic resource] /
_cedited by Marc Humbert, Oleg V. Evgenov, Johannes-Peter Stasch.
264 1 _aBerlin, Heidelberg :
_bSpringer Berlin Heidelberg :
_bImprint: Springer,
_c2013.
300 _aIX, 576 p. 66 illus., 56 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aHandbook of Experimental Pharmacology,
_x0171-2004 ;
_v218
505 0 _aPreface.- Part I. Pulmonary hypertension: conceptual bases of the disease. Pulmonary hypertension: definition, classification, and epidemiology. Pulmonary hypertension: pathophysiology and signalling pathways. Pulmonary hypertension: pathology. Pulmonary hypertension: biomarkers. Pulmonary hypertension: animal models -- Part II. Pulmonary hypertension: established therapies. General supportive care. Calcium channel blockers. Prostacyclins. Endothelin receptor antagonists. Phosphodiesterase 5 inhibitors -- Part III. Pulmonary hypertension: novel pathways and emerging therapies     Soluble guanylate cyclase stimulators. Therapeutics targeting dysregulated redox equilibrium and endothelial dysfunction (NOXs, sGC activators, GSNOR). Rho-kinase inhibitors. Serotonin transporters and serotonin receptors. PDGF inhibitors. Novel anti-proliferative strategies beyond imatinib. Immunosuppressive agents. Vasoactive peptides. Inhibitors of cGMP/cAMP metabolism (MRP4, MRP5, PDE1). Old targets re-visited. Stem cells and cell based therapy -- Part IV. Conclusions and Outlook. Pulmonary hypertension: evidence-based management in the modern era and future directions.
520 _aThis volume focuses on current evidence-based pharmacological treatments of various forms of pulmonary hypertension and provides a comprehensive review of the latest developments in this area. The first part of the book covers the definition, classification, pathophysiology, pathology, biomarkers and animal models of the disease, thus laying the conceptual basis for what follows. The middle section provides an overview of the established therapies, such as calcium channel blockers, prostanoids, endothelin receptor antagonists, phosphodiesterase-5 inhibitors and inhaled nitric oxide. The last section explores novel pathways and emerging therapeutic approaches including soluble guanylate cyclase stimulators, Rho-kinase inhibitors, inhibitors of serotonin receptors and transporters, peptide growth factors, vasoactive peptides, modulators of redox equilibrium and cyclic nucleotide homeostasis, as well as immunosuppressive and anti-proliferative agents. Particular attention is given to the clinical applications of these experimental therapies, that are on the horizon. The book thus spans the continuum from basic science to clinical applications.
650 0 _aMedicine.
650 0 _aLaboratory medicine.
650 0 _aMolecular biology.
650 0 _aPharmacology.
650 0 _aPharmaceutical technology.
650 0 _aInternal medicine.
650 0 _aRespiratory organs
_xDiseases.
650 1 4 _aBiomedicine.
650 2 4 _aPharmacology/Toxicology.
650 2 4 _aPharmaceutical Sciences/Technology.
650 2 4 _aInternal Medicine.
650 2 4 _aPneumology/Respiratory System.
650 2 4 _aLaboratory Medicine.
650 2 4 _aMolecular Medicine.
700 1 _aHumbert, Marc.
_eeditor.
700 1 _aEvgenov, Oleg V.
_eeditor.
700 1 _aStasch, Johannes-Peter.
_eeditor.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9783642386633
830 0 _aHandbook of Experimental Pharmacology,
_x0171-2004 ;
_v218
856 4 0 _uhttp://dx.doi.org/10.1007/978-3-642-38664-0
912 _aZDB-2-SBL
942 _2Dewey Decimal Classification
_ceBooks
999 _c47252
_d47252